Published in AIDS on May 31, 2007
Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a cohort of homosexual men. AIDS (2009) 3.61
HIV serosorting as a harm reduction strategy: evidence from Seattle, Washington. AIDS (2009) 2.58
Behavior change following diagnosis with acute/early HIV infection-a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. AIDS Behav (2009) 2.03
HIV testing trends among gay men in Scotland, UK (1996-2005): implications for HIV testing policies and prevention. Sex Transm Infect (2009) 1.95
A strategy for selecting sexual partners believed to pose little/no risks for HIV: serosorting and its implications for HIV transmission. AIDS Care (2009) 1.77
Seroadaptive practices: association with HIV acquisition among HIV-negative men who have sex with men. PLoS One (2012) 1.64
Serosorting is associated with a decreased risk of HIV seroconversion in the EXPLORE Study Cohort. PLoS One (2010) 1.59
Linkage and retention in HIV care among men who have sex with men in the United States. Clin Infect Dis (2011) 1.59
HIV transmission risk among HIV seroconcordant and serodiscordant couples: dyadic processes of partner selection. AIDS Behav (2008) 1.56
Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany--a case-control study. PLoS One (2011) 1.45
Identifying HIV-1 dual infections. Retrovirology (2007) 1.25
Serosorting and the evaluation of HIV testing and counseling for HIV prevention in generalized epidemics. AIDS Behav (2011) 1.04
Formation of personal HIV disclosure policies among HIV-positive men who have sex with men. AIDS Patient Care STDS (2009) 0.98
Perceived serosorting of injection paraphernalia sharing networks among injection drug users in Baltimore, MD. AIDS Behav (2011) 0.96
Sexual serosorting among women with or at risk of HIV infection. AIDS Behav (2011) 0.95
Changes in seroadaptive practices from before to after diagnosis of recent HIV infection among men who have sex with men. PLoS One (2013) 0.93
A novel approach to prevention for at-risk HIV-negative men who have sex with men: creating a teachable moment to promote informed sexual decision-making. Am J Public Health (2011) 0.91
"You're an open target to be abused": a qualitative study of stigma and HIV self-disclosure among Black men who have sex with men. Am J Public Health (2013) 0.89
Seroadaptation among men who have sex with men: emerging research themes. Curr HIV/AIDS Rep (2013) 0.89
Is serosorting effective in reducing the risk of HIV infection among men who have sex with men with casual sex partners? J Acquir Immune Defic Syndr (2014) 0.88
Stigma trajectories among people living with HIV (PLHIV) embarking on a life time journey with antiretroviral drugs in Jinja, Uganda. BMC Public Health (2013) 0.87
Prevalence of unprotected anal intercourse among men who have sex with men in China: an updated meta-analysis. PLoS One (2014) 0.86
Modeling seroadaptation and sexual behavior among HIV+ study participants with a simultaneously multilevel and multivariate longitudinal count model. Biometrics (2012) 0.84
Relationship Dynamics and Sexual Risk Reduction Strategies Among Heterosexual Young Adults: A Qualitative Study of Sexually Transmitted Infection Clinic Attendees at an Urban Chicago Health Center. AIDS Patient Care STDS (2015) 0.84
Seroadaptation in a sample of very poor Los Angeles area men who have sex with men. AIDS Behav (2013) 0.83
Serosorting and HIV/STI Infection among HIV-Negative MSM and Transgender People: A Systematic Review and Meta-Analysis to Inform WHO Guidelines. J Sex Transm Dis (2013) 0.82
Using HIV Sequence and Epidemiologic Data to Assess the Effect of Self-referral Testing for Acute HIV Infection on Incident Diagnoses in San Diego, California. Clin Infect Dis (2016) 0.78
Beyond Condoms: Risk Reduction Strategies Among Gay, Bisexual, and Other Men Who Have Sex With Men Receiving Rapid HIV Testing in Montreal, Canada. AIDS Behav (2016) 0.75
Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med (2013) 4.26
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
Evaluation of an HIV nucleic acid testing program with automated Internet and voicemail systems to deliver results. Ann Intern Med (2010) 2.69
Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis (2006) 2.26
Role of seminal shedding of herpesviruses in HIV Type 1 Transmission. J Infect Dis (2012) 1.99
Incidence of HIV superinfection following primary infection. JAMA (2004) 1.92
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77
The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med (2010) 1.76
The need for treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS (2015) 1.68
The global transmission network of HIV-1. J Infect Dis (2013) 1.68
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain (2006) 1.60
Herpes viruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract. AIDS (2013) 1.60
Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection. J Infect Dis (2007) 1.59
Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. AIDS (2008) 1.55
Associations between virologic and immunologic dynamics in blood and in the male genital tract. J Virol (2011) 1.55
Characterizing HIV transmission networks across the United States. Clin Infect Dis (2012) 1.54
Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis (2013) 1.53
Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS (2003) 1.52
Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol (2005) 1.52
Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol (2011) 1.44
Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr (2010) 1.36
Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico. J Acquir Immune Defic Syndr (2011) 1.31
Neurocognitive functioning in acute or early HIV infection. J Neurovirol (2010) 1.27
Running with scissors: using antiretroviral therapy without monitoring viral load. Clin Infect Dis (2008) 1.19
Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav (2014) 1.15
Malaria diagnosis by a polymerase chain reaction-based assay using a pooling strategy. Am J Trop Med Hyg (2009) 1.15
Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis (2013) 1.13
Cytomegalovirus DNA in semen and blood is associated with higher levels of proviral HIV DNA. J Infect Dis (2012) 1.10
Clinical, virologic, and immunologic correlates of HIV-1 intraclade B dual infection among men who have sex with men. AIDS (2012) 1.10
Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS (2013) 1.10
Signs or Symptoms of Acute HIV Infection in a Cohort Undergoing Community-Based Screening. Emerg Infect Dis (2016) 1.09
HIV evolution and escape. Trans Am Clin Climatol Assoc (2004) 1.09
Using phylogeography to characterize the origins of the HIV-1 subtype F epidemic in Romania. Infect Genet Evol (2011) 1.07
HIV-1 clade B pol evolution following primary infection. PLoS One (2013) 1.07
Clear Links Between Starting Methamphetamine and Increasing Sexual Risk Behavior: A Cohort Study Among Men Who Have Sex With Men. J Acquir Immune Defic Syndr (2016) 1.07
Phylogenetic relatedness of HIV-1 donor and recipient populations. J Infect Dis (2013) 1.05
Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol (2012) 1.03
Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis (2010) 1.02
Are all subtypes created equal? The effectiveness of antiretroviral therapy against non-subtype B HIV-1. Clin Infect Dis (2009) 0.97
Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. AIDS Res Hum Retroviruses (2010) 0.95
The efficiency of single genome amplification and sequencing is improved by quantitation and use of a bioinformatics tool. J Virol Methods (2009) 0.94
The Use of High Performance Liquid Chromatography to Speciate and Characterize the Epidemiology of Mycobacteria. Lab Med (2011) 0.94
Virologic correlates of anti-CMV IgG levels in HIV-1-infected men. J Infect Dis (2013) 0.93
Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration. Open AIDS J (2007) 0.93
Global NeuroAIDS roundtable. J Neurovirol (2013) 0.92
A combined screening platform for HIV treatment failure and resistance. PLoS One (2012) 0.91
Mitochondrial injury and cognitive function in HIV infection and methamphetamine use. AIDS (2016) 0.90
Real-world impact of neurocognitive deficits in acute and early HIV infection. J Neurovirol (2013) 0.90
Associations between phylogenetic clustering and HLA profile among HIV-infected individuals in San Diego, California. J Infect Dis (2012) 0.90
Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS (2008) 0.89
Cost savings associated with testing of antibodies, antigens, and nucleic acids for diagnosis of acute HIV infection. J Clin Microbiol (2012) 0.89
Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis (2012) 0.88
Dynamics of viral evolution and neutralizing antibody response after HIV-1 superinfection. J Virol (2013) 0.86
The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. AIDS (2011) 0.86
Codon volatility does not reflect selective pressure on the HIV-1 genome. Virology (2005) 0.86
Herpes simplex virus type 2 acquisition during recent HIV infection does not influence plasma HIV levels. J Acquir Immune Defic Syndr (2008) 0.86
Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection. AIDS (2014) 0.86
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol (2012) 0.85
Impact of seminal cytomegalovirus replication on HIV-1 dynamics between blood and semen. J Med Virol (2012) 0.85
Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recovery. AIDS (2010) 0.85
HIV treatment decisions and transmitted drug resistance. Clin Infect Dis (2005) 0.85
Correlates of HIV and malaria co-infection in Southern India. Malar J (2012) 0.83
Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure. AIDS (2010) 0.83
Pooled Nucleic Acid Testing to Detect Antiretroviral Treatment Failure in HIV-Infected Patients in Mozambique. J Acquir Immune Defic Syndr (2015) 0.83
Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection in Seoul, South Korea. Scand J Infect Dis (2013) 0.82
No evidence of posttreatment control after early initiation of antiretroviral therapy. AIDS (2015) 0.82
The relatedness of HIV epidemics in the United States-Mexico border region. AIDS Res Hum Retroviruses (2010) 0.82
Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART. J Acquir Immune Defic Syndr (2016) 0.81
Tissue-specific HIV-1 infection: why it matters. Future Virol (2011) 0.81
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology (2012) 0.81
A novel codon insert in protease of clade B HIV type 1. AIDS Res Hum Retroviruses (2009) 0.80
Sexual transmission of predicted CXCR4-tropic HIV-1 likely originating from the source partner's seminal cells. Virology (2012) 0.80
Partner services in adults with acute and early HIV infection, San Diego, 1996-2014. AIDS (2016) 0.80
Differences in tuberculin reactivity as determined in a veterans administration employee health screening program. Clin Vaccine Immunol (2009) 0.79
Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance. Virology (2009) 0.79
Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India. AIDS Res Hum Retroviruses (2012) 0.79
Using ultradeep pyrosequencing to study HIV-1 coreceptor usage in primary and dual infection. J Infect Dis (2013) 0.78
Simulation of pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection in Seoul, South Korea. J Acquir Immune Defic Syndr (2013) 0.78
Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013. J Acquir Immune Defic Syndr (2016) 0.78
The controversies of nevirapine for preventing mother-to-child HIV transmission. AIDS (2006) 0.78
Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations. AIDS Res Hum Retroviruses (2012) 0.77
Evaluation of pooled rapid HIV antibody screening of patients admitted to a San Diego Hospital. J Virol Methods (2011) 0.77
High prevalence of hepatitis delta virus among patients with chronic hepatitis B virus infection and HIV-1 in an intermediate hepatitis B virus endemic region. J Int Assoc Provid AIDS Care (2013) 0.77
Neurobehavioral Disturbances During Acute and Early HIV Infection. Cogn Behav Neurol (2016) 0.77
Novel codon insert in HIV type 1 clade B reverse transcriptase associated with low-level viremia during antiretroviral therapy. AIDS Res Hum Retroviruses (2013) 0.77
Standard vaccines increase HIV-1 transcription during antiretroviral therapy. AIDS (2016) 0.77
HIV-1 reverse transcriptase nucleotide substitutions in subtype C-infected, drug-naive, and treatment-experienced patients in South India. J Acquir Immune Defic Syndr (2011) 0.75
Reply to Mounzer and DiNubile. J Infect Dis (2013) 0.75
HIV Trafficking Between Blood and Semen During Early Untreated HIV Infection. J Acquir Immune Defic Syndr (2017) 0.75
The association between HIV-1 subtype C antiretroviral resistance and HLA prevalence in southern India. J Acquir Immune Defic Syndr (2011) 0.75
Dual-mixed HIV-1 coreceptor tropism and HIV-associated neurocognitive deficits. J Neurovirol (2013) 0.75
Reverse transcriptase substitution at codons 208 and 228 among treatment-experienced HIV-1 subtype-C-infected Indian patients is strongly associated with thymidine analogue mutations. J Acquir Immune Defic Syndr (2012) 0.75
HIV-associated neurocognitive disorder is associated with HIV-1 dual infection. AIDS (2016) 0.75
Antibody response to Achromobacter xylosoxidans during HIV infection is associated with lower CD4 levels and increased lymphocyte activation. Clin Vaccine Immunol (2013) 0.75
Can research at the end of life be a useful tool to advance HIV cure? AIDS (2017) 0.75
Short communication: prospective comparison of qualitative versus quantitative polymerase chain reaction for monitoring virologic treatment failure in HIV-infected patients. AIDS Res Hum Retroviruses (2014) 0.75
Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles. AIDS (2017) 0.75
Corrigendum: Circulating HIV DNA Correlates With Neurocognitive Impairment in Older HIV-infected Adults on Suppressive ART. Sci Rep (2016) 0.75